“Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 2 Trial”. SKIN The Journal of Cutaneous Medicine 9, no. 6 (November 10, 2025): s692. Accessed April 30, 2026. https://skin.dermsquared.com/skin/article/view/3778.